arrow
D

Daphne W. Dumoulin

erasmus university medical center
H指数:19
被引数:2,303

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Diagnostic Challenges in WHO Classification of Thymic Epithelial Tumors: The Clinical Value of an International Expert Pathology Panel

WHO胸腺上皮肿瘤分类中的诊断挑战:国际专家病理学专家组的应用价值

2026-10-170
OA
Analysis of SLFN11 expression in small cell lung cancer, carcinoids and large cell neuroendocrine carcinoma: insights into lung neuroendocrine neoplasms

SLFN11在肺小细胞癌、类癌和大细胞神经内分泌癌中的表达分析:对肺神经内分泌肿瘤的见解

2026-07-130
OAAI
Model-Informed Approaches to Develop Drug Cost-Saving Dosing Strategies for Pembrolizumab

基于模型的方法开发帕博利珠单抗的药物成本节约给药策略

2026-05-230
OAAI
Evolving Treatment Strategies and the Impact of Centralization on Outcomes in Thymic Epithelial Tumors: A Nationwide Population-Based Study from the Netherlands

胸腺上皮肿瘤的治疗策略演变及集中化对预后的影响:一项来自荷兰的全国性基于人群的研究

2026-04-300
OAAI
TDM-Based Tailored Dosing of Durvalumab in Lung Cancer Patients: A Comprehensive Population Pharmacokinetic–Pharmacoeconomic Evaluation

基于治疗药物监测的度鲁特玛在肺癌患者中的个体化给药:一项全面的群体药代动力学–药效经济学评估

2025-07-250
OAAI
TEIPP-vaccination in checkpoint-resistant non-small cell lung cancer: a first-in-human phase I/II dose-escalation study

Emmers, M.; Welters, M.J.P.; Dietz, M.V.; Santegoets, S.J.; Boekesteijn, S.; Stolk, A.; Loof, N.M.; Dumoulin, D.W.; Geel, A.L.; Steinbusch, L.C.; et al. TEIPP-vaccination在耐药性非小细胞肺癌中的研究:一项首次人体I/II期剂量递增研究。Nat. Commun. 2025, 16, 4958. [Google Scholar] [CrossRef]

2025-05-280
OAAI
The relationship between nivolumab pharmacokinetics and cancer cachexia biomarkers in patients with metastatic non-small cell lung cancer (NSCLC)

纳武利尤单抗药代动力学与转移性非小细胞肺癌(NSCLC)患者癌症恶病质生物标志物之间的关系

2024-09-010
PRE
Hepatotoxicity in patients with non-small cell lung cancer treated with sotorasib after prior immunotherapy: a comprehensive clinical and pharmacokinetic analysis
2024-04-017
OAAI
SAPPHIRE: Phase III study of sitravatinib plus nivolumab versus docetaxel in patients with previously treated advanced non-squamous non-small cell lung cancer (NSCLC)
2023-10-010
PRE